Sinco Pharmaceuticals Holdings Ltd
HKEX:6833
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sinco Pharmaceuticals Holdings Ltd
HKEX:6833
|
CN |
|
Fuchs Petrolub SE
XETRA:FPE
|
DE |
Balance Sheet
Balance Sheet Decomposition
Sinco Pharmaceuticals Holdings Ltd
Sinco Pharmaceuticals Holdings Ltd
Balance Sheet
Sinco Pharmaceuticals Holdings Ltd
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & Cash Equivalents |
27
|
28
|
58
|
38
|
102
|
23
|
80
|
220
|
144
|
326
|
329
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
144
|
0
|
0
|
|
| Cash Equivalents |
27
|
28
|
58
|
38
|
102
|
23
|
80
|
220
|
0
|
326
|
329
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
111
|
0
|
0
|
2
|
0
|
0
|
0
|
|
| Total Receivables |
1
|
37
|
102
|
99
|
58
|
97
|
30
|
58
|
588
|
225
|
390
|
|
| Accounts Receivables |
0
|
4
|
0
|
0
|
12
|
26
|
23
|
26
|
579
|
213
|
350
|
|
| Other Receivables |
1
|
34
|
102
|
99
|
46
|
70
|
7
|
32
|
9
|
12
|
40
|
|
| Inventory |
0
|
149
|
101
|
47
|
138
|
291
|
215
|
259
|
243
|
61
|
88
|
|
| Other Current Assets |
85
|
59
|
28
|
36
|
81
|
140
|
61
|
87
|
32
|
357
|
210
|
|
| Total Current Assets |
113
|
273
|
288
|
220
|
490
|
551
|
386
|
626
|
1 006
|
969
|
1 017
|
|
| PP&E Net |
10
|
59
|
100
|
97
|
104
|
192
|
182
|
198
|
238
|
256
|
316
|
|
| PP&E Gross |
10
|
59
|
100
|
97
|
104
|
192
|
182
|
198
|
238
|
256
|
316
|
|
| Accumulated Depreciation |
0
|
1
|
3
|
8
|
14
|
23
|
34
|
42
|
49
|
54
|
58
|
|
| Intangible Assets |
0
|
0
|
0
|
40
|
32
|
0
|
0
|
0
|
0
|
0
|
15
|
|
| Goodwill |
0
|
0
|
0
|
36
|
59
|
24
|
0
|
0
|
0
|
0
|
67
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
7
|
6
|
6
|
|
| Other Long-Term Assets |
0
|
45
|
53
|
72
|
103
|
53
|
44
|
1
|
1
|
1
|
3
|
|
| Other Assets |
0
|
0
|
0
|
36
|
59
|
24
|
0
|
0
|
0
|
0
|
67
|
|
| Total Assets |
123
N/A
|
377
+207%
|
441
+17%
|
465
+5%
|
788
+69%
|
819
+4%
|
612
-25%
|
832
+36%
|
1 252
+50%
|
1 233
-2%
|
1 424
+16%
|
|
| Liabilities | ||||||||||||
| Accounts Payable |
0
|
8
|
19
|
63
|
46
|
23
|
107
|
300
|
700
|
423
|
408
|
|
| Accrued Liabilities |
0
|
0
|
0
|
1
|
2
|
2
|
23
|
25
|
3
|
3
|
8
|
|
| Short-Term Debt |
0
|
52
|
92
|
82
|
165
|
410
|
145
|
187
|
77
|
208
|
181
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
1
|
3
|
|
| Other Current Liabilities |
118
|
269
|
207
|
125
|
118
|
113
|
314
|
142
|
209
|
91
|
191
|
|
| Total Current Liabilities |
118
|
329
|
318
|
271
|
330
|
546
|
589
|
656
|
991
|
726
|
791
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
132
|
9
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
|
| Minority Interest |
1
|
8
|
18
|
0
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
130
|
93
|
0
|
19
|
|
| Total Liabilities |
119
N/A
|
336
+184%
|
336
N/A
|
272
-19%
|
330
+21%
|
546
+66%
|
588
+8%
|
785
+33%
|
1 087
+38%
|
858
-21%
|
821
-4%
|
|
| Equity | ||||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
4
|
41
|
105
|
179
|
195
|
11
|
270
|
246
|
128
|
5
|
78
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
15
|
259
|
259
|
289
|
289
|
289
|
366
|
525
|
|
| Other Equity |
0
|
0
|
0
|
0
|
4
|
4
|
4
|
4
|
4
|
4
|
0
|
|
| Total Equity |
4
N/A
|
41
+849%
|
105
+158%
|
193
+84%
|
458
+137%
|
274
-40%
|
24
-91%
|
47
+100%
|
165
+250%
|
375
+127%
|
604
+61%
|
|
| Total Liabilities & Equity |
123
N/A
|
377
+207%
|
441
+17%
|
465
+5%
|
788
+69%
|
819
+4%
|
612
-25%
|
832
+36%
|
1 252
+50%
|
1 233
-2%
|
1 424
+16%
|
|
| Shares Outstanding | ||||||||||||
| Common Shares Outstanding |
1 600
|
1 600
|
1 600
|
1 200
|
1 615
|
1 615
|
1 692
|
1 692
|
1 692
|
1 873
|
2 033
|
|